Search

Your search keyword '"Dalmau, Judith"' showing total 181 results

Search Constraints

Start Over You searched for: Author "Dalmau, Judith" Remove constraint Author: "Dalmau, Judith"
181 results on '"Dalmau, Judith"'

Search Results

1. TL1A–DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1–Specific T Cell Responses

2. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study

3. Differential Immunodominance Hierarchy of CD8+ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection

5. Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART

6. Author response: Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART

7. Common genetic variation and the control of HIV-1 in humans.

8. Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy

9. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load

10. Single-cell CD8+ dynamics in PLWH uncover the depletion of TIGIT+ memory HIV-1-specific cells during long-term ART

12. Altered T‐cell subset distribution in the viral reservoir in HIV‐1‐infected individuals with extremely low proviral DNA (LoViReTs)

13. A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection

15. Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors

16. Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With HIV on Suppressive Antiretroviral Therapy

18. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque

20. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

21. The genome-wide methylation profile of CD4+ T cells from HIV-infected individuals identifies distinct patterns associated with disease progression

22. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

23. Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles

24. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A

25. Abstract 929: Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients

26. The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression

27. Extremely low viral reservoir in treated chronically HIV-1-infected individuals

28. Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab

30. The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression.

31. Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus–related Lymphomas

33. Differential Immunodominance Hierarchy of CD8 + T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection

35. HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells

36. Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus–related Lymphomas.

37. Identification of Siglec-1 null individuals infected with HIV-1

38. Identification of Siglec-1 null individuals infected with HIV-1

39. How strict is galactose restriction in adults with galactosaemia? International practice

40. Practices in prescribing protein substitutes for PKU in Europe : No uniformity of approach

41. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load

42. Practices in prescribing protein substitutes for PKU in Europe: No uniformity of approach

43. How strict is galactose restriction in adults with galactosaemia? International practice

44. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load

45. HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells

47. Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells

48. Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls

49. A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control

50. Author response: A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control

Catalog

Books, media, physical & digital resources